Leitlinie „Behandlung der Akne“ - AWMF

013/017 - Behandlung der Akne aktueller Stand: 02/2010
korrigierte Fassung: 10/2011
454. Mills O, Jr., Thornsberry C, Cardin CW, Smiles KA, Leyden JJ. Bacterial resistance
and therapeutic outcome following three months of topical acne therapy with 2%
erythromycin gel versus its vehicle. Acta Derm Venereol. 2002; 82: 260-5.
455. Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibiotics on the
oropharyngeal flora in patients with acne. Arch Dermatol. 2003; 139: 467-71.
456. Oprica C, Emtestam L, Hagstromer L, Nord CE. Clinical and microbiological
comparisons of isotretinoin vs. tetracycline in acne vulgaris. Acta Derm Venereol.
2007; 87: 246-54.
457. Ozolins M, Eady EA, Avery A, Cunliffe WJ, O'Neill C, Simpson NB, Williams HC.
Randomised controlled multiple treatment comparison to provide a cost-effectiveness
rationale for the selection of antimicrobial therapy in acne. Health Technol Assess.
2005; 9: iii-212.
458. Oprica C, Nord CE. European surveillance study on the antibiotic susceptibility of
Propionibacterium acnes. Clin Microbiol Infect. 2005; 11: 204-13.
459. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical
measure for routine clinical use. Clin Exp Dermatol. 1994; 19: 210-6.
460. Augustin M, Wenninger K, Amon U, Schroth MJ, Kuster W, Chren M, Kupfer J,
Gieler U. German adaptation of the Skindex-29 questionnaire on quality of life in
dermatology: validation and clinical results. Dermatology. 2004; 209: 14-20.
461. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and
evaluative capability of a refined version of Skindex, a quality-of-life instrument for
patients with skin diseases. Arch Dermatol. 1997; 133: 1433-40.
462. Anderson RT, Aaronson NK, Bullinger M, McBee WL. A review of the progress
towards developing health-related quality-of-life instruments for international clinical
studies and outcomes research. Pharmacoeconomics. 1996; 10: 336-55.
463. Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales--a
measure of the impact of skin diseases. Br J Dermatol. 1997; 136: 202-6.
464. Rothmann KF, Pochi PE. Use of oral and topical agents for acne in pregnancy. J Am
Acad Dermatol. 1988; 19: 431-42.
465. Barza M, Goldstein JA, Kane A, Feingold DS, Pochi PE. Systemic absorption of
clindamycin hydrochloride after topical application. J Am Acad Dermatol. 1982; 7:
208-14.
466. Borglund E, Hagermark O, Nord CE. Impact of topical clindamycin and systemic
tetracycline on the skin and colon microflora in patients with acne vulgaris. Scand J
Infect Dis Suppl. 1984; 43: 76-81.
467. Becker LE, Bergstresser PR, Whiting DA, Clendenning WE, Dobson RL, Jordan WP,
Abell E, LeZotte LA, Pochi PE, Shupack JL, Sigafoes RB, Stoughton RB, Voorhees
JJ. Topical clindamycin therapy for acne vulgaris. A cooperative clinical study. Arch
Dermatol. 1981; 117: 482-5.
468. Milstone EB, McDonald AJ, Scholhamer CF, Jr. Pseudomembranous colitis after
topical application of clindamycin. Arch Dermatol. 1981; 117: 154-5.
469. Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin
phosphate. Arch Dermatol. 1986; 122: 583-4.
Seite 134 von 136